Kristin Bretz, MD
Ophthalmology · Salt Lake City, UTNPI 1578856431
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (54.0%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by AbbVie at 32.1% of the total. 2025 is the largest year on record at $1,873, 4.4 times the $430 reported in 2019.
Across 79 payments — averaging $65.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- W. L. Gore & Associates, Inc.$1K
- Alcon$863
- NEW World Medical,inc.$473
- Glaukos Corporation$345
- Novartis$104
- plus $465 from 9 others
Across 214 payments — averaging $793.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alcon Research LLC$106K
- Glaukos Corporation$64K
What the payments were for
- Consulting fees$2,33545%
- Travel & lodging$291%
- Food & beverage$2,78854%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 36 | $1,656 |
| W. L. Gore & Associates, Inc. | 1 | $1,260 |
| Alcon | 10 | $863 |
| NEW World Medical,inc. | 7 | $473 |
| Glaukos Corporation | 9 | $345 |
| Novartis | 2 | $104 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $101 |
| Sight Sciences, Inc. | 3 | $98 |
| Aerie Pharmaceuticals, Inc. | 3 | $92 |
| Hoffmann-la Roche Limited | 1 | $46 |
| Bausch & Lomb Americas Inc. | 2 | $39 |
| Carl Zeiss Meditec USA, Inc. | 1 | $27 |
| Sun Pharmaceutical Industries Inc. | 1 | $23 |
| Dompe US, Inc. | 1 | $22 |
| Oyster Point Pharma, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Product in Development$1,260
- RESTASIS$800
- Hydrus Microstent$400
- Clareon$247
- Kahook Dual Blade$164
- Clearpath$164
- Ahmed Glaucoma Valve$164
- Streamline$164
- PanOptix$151
- DURYSTA$125
- LOTEMAX SM$101
- VYZULTA$101
- PROLENSA$101
How this compares
$5,166 in reported general payments places this provider in the 85th percentile of 191 ophthalmology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 85 | $48,690 |
| RocklatanNetarsudil Mesylat/Latanoprost | 58 | $30,915 |
| Prednisolone Acetate | 421 | $18,082 |
| Latanoprost | 983 | $12,096 |
| CombiganBrimonidine Tartrate/Timolol | 32 | $12,086 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 76 | $10,236 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 533 | $9,307 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 32 | $8,562 |
| RhopressaNetarsudil Mesylate | 17 | $7,591 |
| Travoprost | 51 | $6,671 |
| VyzultaLatanoprostene Bunod | 11 | $5,328 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 16 | $4,871 |
| TafluprostTafluprost/Pf | 11 | $4,447 |
| Brimonidine Tartrate | 235 | $4,411 |
| Ofloxacin | 314 | $3,298 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan | $1,656 | $60,776117 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $92 | $38,50675 claims |
| AlconSimbrinza | $863 | $8,56232 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $39 | $5,32811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 191 ophthalmology providers in Utah.
Other ophthalmology in Salt Lake City
- Iqbal AhmedSalt Lake City$895K
- Robert CionniSalt Lake City$161K
- Zachary ZavodniSalt Lake City$51K
- Majid MoshirfarSalt Lake City$44K
- Marc Steffen Schmitz-ValckenbergSalt Lake City$43K
- Rachel SimpsonSalt Lake City$39K
- Austin NakatsukaSalt Lake City$27K
- Douglas MarxSalt Lake City$22K
- Akbar ShakoorSalt Lake City$18K
- Craig ChayaSalt Lake City$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.